Electra Therapeutics has set terms for a proposed $325 million initial public offering, adding another late-stage biotech transaction to a U.S. IPO market that has begun to show renewed activity in the sector. The South San Francisco-based company plans to offer 21.7 million shares at $14 to $16 each, implying a fully diluted market value of approximately $976.1 million at the midpoint. The offering is expected to price on September 17, with proceeds aimed primarily at advancing Electra’s clinical pipeline.
Company Background
Founded in 2018, Electra Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines aimed at signal regulatory proteins, or SIRPs, found on specific immune-cell populations. Its approach is designed to selectively remove disease-driving immune cells while preserving normal immune function, giving the company exposure to both immunological diseases and oncology.
The company’s lead program, ipsoprubart, is a pan-SIRP monoclonal antibody being evaluated in the registrational Phase 2/3 SURPASS trial for secondary hemophagocytic lymphohistiocytosis. Earlier Phase 1b data in 12 frontline malignancy-associated HLH patients showed 100% eight-week overall survival and a 100% overall response rate. Ipsoprubart is also being evaluated in a Phase 1 study involving relapsed or refractory T-cell and natural killer-cell malignancies. Electra’s second candidate, ELA822, targets SIRPγ and entered a Phase 1 trial in Europe in August 2026.
Electra is led by President and Chief Executive Officer Quehuong (Kathy) Dong, who has more than two decades of experience across biotechnology corporate development, operations, portfolio management and commercialization. Chief Financial Officer Chris Clark joined the company with more than two decades of biopharmaceutical capital-markets and corporate-strategy experience. Existing institutional investors include Sanofi, EQT’s LSP, OrbiMed, Redmile, Westlake BioPartners and Nextech, reflecting substantial specialist healthcare backing ahead of the IPO.
IPO Details
Electra plans to list its common stock on the Nasdaq Global Select Market under the ticker ETRA. The proposed offering consists of 21.7 million shares priced between $14 and $16, with the midpoint implying a fully diluted market value of $976.1 million. Jefferies, TD Cowen, Evercore ISI and Cantor Fitzgerald are serving as joint bookrunners. The transaction is expected to price on September 17, although the final IPO price and resulting valuation will depend on investor demand and final offering terms.
The capital is particularly important because Electra remains a development-stage biotechnology company rather than a commercial pharmaceutical business. Its ability to advance ipsoprubart through late-stage testing and develop ELA822 will therefore remain central to the investment case and to the company’s transition from private funding toward the public stock market.
Market Context & Opportunities
The proposed IPO arrives as biotechnology companies return to U.S. equity markets after a difficult period for new listings. Electra’s late-stage clinical profile gives public-market investors exposure to programs that have moved beyond early discovery, while its SIRP platform creates potential applications across multiple immune-mediated diseases and cancers. The involvement of established healthcare investors and major investment banks also provides institutional credibility as the company approaches its market debut.
Risks & Challenges
Clinical and regulatory risk remains the primary consideration. Ipsoprubart’s earlier results involve a limited patient population and do not establish that the Phase 2/3 program will achieve its required endpoints or ultimately support regulatory approval. Electra also faces competition from other approaches to immune-cell modulation, while development costs could require additional financing if clinical programs extend or commercial timelines move out. As with other biotechnology IPOs, the stock may therefore remain highly sensitive to clinical data, regulatory decisions and broader market appetite for unprofitable growth companies.
Closing Paragraph
Electra’s IPO represents a meaningful test of investor appetite for late-stage biotechnology platforms rather than a conventional growth-company listing. A proposed valuation of approximately $976.1 million at the midpoint places significant emphasis on the clinical potential of ipsoprubart and the broader SIRP platform. Whether ETRA ultimately attracts strong investor interest will depend less on the size of the IPO than on the market’s assessment of clinical probability, regulatory visibility and the potential commercial reach of Electra’s pipeline.
